General MedicationsORALStandard
JASCAYD
NERANDOMILAST
Standard Dose
9MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview JASCAYD is listed in Drugs@FDA under application 218764 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient NERANDOMILAST Form and strength TABLET;ORAL - 9MG Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2026-02-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview JASCAYD is listed in Drugs@FDA under application 218764 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NERANDOMILAST Form and strength TABLET;ORAL - 9MG Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2026-02-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.